Technical Data
Bone Morphogenetic Protein 7, Recombinant, Mouse (BMP7, OP-1, Osteogenic Protein-1)
Molecular Biology Storage: -20°CShipping: Blue Ice
Bone morphogenetic protein 7 (BMP­7), also known as osteogenic protein 1 (OP­1), is a widely expressed TGF­beta super family member with important functions during embryogenesis, in the adult, and in disease. Mouse BMP­7 is synthesized with a 29aa signal sequence, a 262 aa propeptide, and a 139 aa growth fact or domain. The growth factor domain of mouse BMP­7 shares 98% and 100% aa sequence identity with human and rat BMP­7, respectively. The BMP­7 propeptide is cleaved intracellularly but remains in association with the growth factor domain. BMP­7 is subsequently secreted as a tetramer that consists of two propeptides and two disulfide­linked growth factor domains. Mature BMP­7 can also form disulfide­linked heterodimers with BMP­2 or BMP­4, complexes that show increased potency and range of activity compared to BMP­7 homodimers. The presence of the propeptides in the BMP­7 tetramer does not diminish the bioactivity of the growth factor domains. Secreted BMP­7 is immobilized in the extracellular matrix as a result of interactions between the propeptide and matrix fibrillin. BMP­7 exerts its biological effects through the type 2 receptors Activin RIIA, Activin RIIB, and BMPR­I I and the t ype 1 receptors Activin RIA, BMPR­IA, and BMPR­IB. BMP­7 plays a role in a variety of organ systems. It promotes new bone formation and nephron development, inhibits the branching of prostate epithelium, and antagonizes epithelial­mesenchymal transition (EMT). In pathological conditions, BMP­7 inhibits tumor growth and metastasis, ameliorates fibrotic damage in nephritis and promotes neuroregeneration following brain ischemia.

Structure: Disulfide-linked homodimer

SDS-PAGE: 16-20kD under reducing conditions

Activity: Measured by its ability to induce alkaline phosphatase production by ATDC5 mouse chondrogenic cells. The ED50 for this effect is typically 0.125 0.5ug/ml.

Endotoxin: 1.0 EU/ug (LAL)

Suitable for use in ELISA. Other applications not tested.

Recommended Dilutions:
Optimal dilutions to be determined by the researcher.

Storage and Stability:
Lyophilized powder may be stored at -20°C. Stable for 12 months at -20°C. Reconstitute with 4mM HCl. Aliquot to avoid repeated freezing and thawing. Store at -20°C. Reconstituted product is stable for 6 months at -20°C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer.

Molecular Weight:
Source: Recombinant corresponding to aa292-430 from mouse Bone Morphogenetic Protein 7 expressed in CHO cells (NP_031583).
Purity: 95% by SDS­PAGE under reducing conditions and visualized by silver stain.
Concentration: ~0.1mg/ml (after reconstitution)
Form: Supplied as a lyophilized powder from 4mM HCl. Reconstitute with 4mM HCl.

Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications without the expressed written authorization of United States Biological.
1. Chen, D. et al. (2004) Growth Factors 22:233. 2. Kishigami, S. and Y. Mishina (2005) Cytokine Growth Factor Rev. 16:265. 3. Ozkaynak, E. et al. (1991) Biochem. Biophys. Res. Commun. 179:116. 4. Gregory, K.E. et al. (2005) J. Biol. Chem. 280:27970. 5. Sengle, G. et al. (2008) J. Mol. Biol. 381:1025. 6. Israel, D.I. et al. (1996) Growth Factors 13:291. 7. Aono, A. et al. (1995) Biochem. Biophys. Res. Commun. 210:670. 8. Nishimatsu, S. and G.H. Thomsen (1998) Mech. Dev. 74:75. 9. Sampat h, T. K. et al. (1992) J. Biol. Chem. 267:20352. 10. Kazama, I. et al. (2008) J. Am. Soc. Nephrol. 19:2181. 11. Grishina, I.B. et al. (2005) Dev. Biol. 288:334. 12. Zeisberg, M. et al. (2003) Nat. Med. 9:964. 13. Buijs, J.T. et al. (2007) Am. J. Pathol. 171:1047. 14. Nakamura, K. et al. (1999) Exp. Cell Res. 250:351.

Intended for research use only. Not for use in human, therapeutic, or diagnostic applications.